| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRAT |
| Uniprot No | P43155 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-626aa |
| 氨基酸序列 | MLAFAARTVV KPLGFLKPFS LMKASSRFKA HQDALPRLPV PPLQQSLDHY LKALQPIVSE EEWAHTKQLV DEFQASGGVG ERLQKGLERR ARKTENWLSE WWLKTAYLQY RQPVVIYSSP GVMLPKQDFV DLQGQLRFAA KLIEGVLDFK VMIDNETLPV EYLGGKPLCM NQYYQILSSC RVPGPKQDTV SNFSKTKKPP THITVVHNYQ FFELDVYHSD GTPLTADQIF VQLEKIWNSS LQTNKEPVGI LTSNHRNSWA KAYNTLIKDK VNRDSVRSIQ KSIFTVCLDA TMPRVSEDVY RSHVAGQMLH GGGSRLNSGN RWFDKTLQFI VAEDGSCGLV YEHAAAEGPP IVTLLDYVIE YTKKPELVRS PLVPLPMPKK LRFNITPEIK SDIEKAKQNL SIMIQDLDIT VMVFHHFGKD FPKSEKLSPD AFIQMALQLA YYRIYGQACA TYESASLRMF HLGRTDTIRS ASMDSLTFVK AMDDSSVTEH QKVELLRKAV QAHRGYTDRA IRGEAFDRHL LGLKLQAIED LVSMPDIFMD TSYAIAMHFH LSTSQVPAKT DCVMFFGPVV PDGYGVCYNP MEAHINFSLS AYNSCAETNA ARLAHYLEKA LLDMRALLQS HPRAKL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CRAT(肉碱乙酰转移酶)重组蛋白的3篇代表性文献概览：
1. **《Functional expression and characterization of recombinant human carnitine acetyltransferase》**
- 作者：Jogl G, Tong L
- 摘要：报道了人源CRAT重组蛋白在大肠杆菌中的高效表达与纯化，通过X射线晶体学解析其三维结构，揭示了底物结合位点的关键氨基酸残基。
2. **《Role of carnitine acetyltransferase in mitochondrial transport》**
- 作者：Kerner J, Hoppel C
- 摘要：研究CRAT在细胞线粒体代谢中的作用，利用重组蛋白实验证明其通过调节乙酰-CoA/CoASH平衡影响能量代谢通路，为代谢疾病机制提供依据。
3. **《Optimization of recombinant mouse Crat production in Pichia pastoris》**
- 作者：Rodríguez S et al.
- 摘要：优化毕赤酵母表达系统生产小鼠CRAT重组蛋白的工艺，获得高活性产物，并验证其在体外模型中对脂肪酸氧化缺陷的纠正作用。
*注：若需更近期文献或特定研究方向，建议在PubMed等数据库检索关键词“recombinant CRAT protein expression”或结合具体应用场景(如疾病模型、结构生物学等)筛选。*
Carnitine O-acetyltransferase (CRAT) is a mitochondrial enzyme critical for cellular energy metabolism, primarily facilitating the transport of acyl groups across mitochondrial membranes. It catalyzes the reversible transfer of acyl groups between coenzyme A (CoA) and carnitine, producing acyl-carnitine derivatives. This process is essential for shuttling long-chain fatty acids into mitochondria for β-oxidation and regulating the intracellular balance of acyl-CoA/CoA, which influences multiple metabolic pathways, including glucose utilization and lipid synthesis.
Recombinant CRAT protein refers to a lab-engineered version of this enzyme produced through genetic engineering techniques. By inserting the CRAT gene into expression systems like *E. coli*, yeast, or mammalian cells, researchers generate purified, functional CRAT with consistent quality. This approach overcomes limitations of isolating the enzyme from natural sources, such as low yield or contamination. Recombinant CRAT retains catalytic activity and structural integrity, enabling precise study of its biochemical properties, substrate specificity, and regulatory mechanisms.
Therapeutic and research applications of recombinant CRAT are emerging. It serves as a tool to investigate metabolic disorders linked to CRAT dysfunction, such as insulin resistance, cardiomyopathy, or rare genetic deficiencies. In drug discovery, it aids in screening compounds targeting metabolic pathways. Recent studies explore its potential in mitigating metabolic syndrome or age-related mitochondrial decline. Challenges include optimizing protein stability and delivery systems for clinical use. Ongoing work also focuses on structural studies to engineer CRAT variants with enhanced activity or tailored functions, expanding its utility in biomedicine and biotechnology.
×
